PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
PDS Biotechnology Corporation (Nasdaq: PDSB) announced participation in Cantor’s Future of Oncology Virtual Symposium from April 3-5, 2023. Dr. Frank Bedu-Addo, President and CEO, will present on April 4 at 3:00 PM ET. The company focuses on developing targeted immunotherapies for cancer and infectious diseases through innovative platforms like Versamune® and Infectimune™. Their lead candidate, PDS0101, has shown promise in treating HPV16-associated cancers, demonstrating tumor reduction and disease stabilization. PDS Biotech aims to enhance immunotherapy effectiveness by optimizing T cell responses.
- None.
- None.
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate in Cantor’s Future of Oncology Virtual Symposium being held on April 3-5, 2023.
Cantor Symposium
Presentation Date: Tuesday, April 4, 2023
Time: 3:00 PM ET
For more information about the conference, please contact your Cantor representative directly.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune™ T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
Media Contacts:
Tiberend Strategic Advisors, Inc.
Dave Schemelia
Phone: +1 (609) 468-9325
dschemelia@tiberend.com
Bill Borden
Phone: +1 (732) 910-1620
bborden@tiberend.com
FAQ
What is the date of the Cantor Future of Oncology Virtual Symposium that PDSB is participating in?
Who will represent PDS Biotechnology at the Cantor Symposium?
When is PDSB's presentation at the Cantor Symposium?
What are the main areas of focus for PDS Biotechnology?
What is the lead clinical candidate of PDSB?
